The US Food and Drug Administration has approved daraxonrasib, a first-of-a-kind oral drug that blocks a mutated protein driving tumor growth in more than 90% of pancreatic cancer cases, offering patients a new treatment option against one of the deadliest cancers.
FDA grants expedited approval to first pill targeting mutated protein in pancreatic cancer
The US Food and Drug Administration has approved daraxonrasib, a first-of-a-kind oral drug that blocks a mutated protein driving tumor growth in more than 90% of pancreatic cancer cases, offering patients a new treatment option against one of the deadliest cancers.
The U.S. Food and Drug Administration · Public domain · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.